Luca Valenti Profile
Luca Valenti

@lucavalenti75

Followers
1K
Following
5K
Media
37
Statuses
2K

MD, researcher, editor; Hepatology & Internal Medicine, Genetics; father of two; views are my own

Milano
Joined March 2015
Don't wanna be here? Send us removal request.
@lucavalenti75
Luca Valenti
1 day
RT @EricTopol: Adherence to a Mediterranean diet linked to reduced dementia-related metabolites, many of which showed causal relationships….
0
136
0
@lucavalenti75
Luca Valenti
4 days
RT @rabataller: 🚨 AI won’t replace doctors… but it can prevent them from learning how to think. A critical article in @NEJM shows that if….
0
426
0
@grok
Grok
2 days
Join millions who have switched to Grok.
107
196
1K
@lucavalenti75
Luca Valenti
5 days
RT @NEJMEvidence: Statistical testing of more than one hypothesis has the potential to increase the risk of type I error. Amy LaLonde, PhD,….
0
20
0
@lucavalenti75
Luca Valenti
5 days
RT @davidasinclair: ⁦Optimizing Yamanaka factors for epigenetic age reversal . Congrats @OpenAI⁩ ⁦@RetroBio_⁩ 👏
Tweet card summary image
openai.com
OpenAI and Retro Biosciences achieve 50x increase in expressing stem cell reprogramming markers.
0
109
0
@lucavalenti75
Luca Valenti
6 days
Check it out: a short overview of the PNPLA3 research field and our Special Issue! Fifteen Years of PNPLA3: Transforming Hepatology Through Human Genetics @LiverInt
Tweet card summary image
onlinelibrary.wiley.com
Steatotic liver disease (SLD), caused by excess lipid accumulation in hepatocytes, is now a leading global liver condition triggered by metabolic dysfunction, alcohol, toxins and heritable factors....
1
5
20
@lucavalenti75
Luca Valenti
6 days
RT @EricTopol: A discovery of a gene underpinning the perception of pain with implications for treating the chronic condition that affects….
Tweet card summary image
nature.com
Nature - The SLC45A4 gene encodes a neuronal polyamine transporter and is linked to pain response in humans and mice.
0
66
0
@lucavalenti75
Luca Valenti
6 days
RT @andganna: Impressive paper by EPIC. They built a autoregressive transformer on 150M individuals and 115 billion.medical events. Inclu….
0
10
0
@lucavalenti75
Luca Valenti
8 days
RT @EricTopol: Rejuvenating the brain of old mice by targeting ferritin light chain (FTL1)."Our data raise the exciting possibility that th….
0
19
0
@lucavalenti75
Luca Valenti
8 days
RT @NikoMcCarty: Mitochondria are known as the "powerhouses" of a cell. But that is a ridiculously incomplete description. A new study sho….
0
263
0
@lucavalenti75
Luca Valenti
8 days
This is worrisome.
@EricTopol
Eric Topol
9 days
The rise in A.I. preprints and plagiarism.
Tweet media one
Tweet media two
0
1
1
@lucavalenti75
Luca Valenti
8 days
RT @NEJM: A new review discusses the global clinical burden and consequences of MASLD as a multisystem disease and focuses on the new and p….
0
25
0
@lucavalenti75
Luca Valenti
11 days
RT @MarcoArreseMD: @rabataller @EASLedu @AASLDtweets @AEEHLiver Fully agree. This table from Mangia & Valenti just published review is comp….
0
4
0
@lucavalenti75
Luca Valenti
11 days
RT @NEJM: Correspondence: A Naturally Occurring Gain-of-Function Mutation in Factor VIII . #Hematology #Cardiology….
0
5
0
@lucavalenti75
Luca Valenti
12 days
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis - Mangia - 2025 - Liver International - Wiley Online Library @LiverInt.
Tweet card summary image
onlinelibrary.wiley.com
Metabolic dysfunction associated steatohepatitis (MASH), formerly known as NASH, represents one of the leading causes of chronic liver disease worldwide. Its high prevalence is driven by insulin...
0
1
14
@lucavalenti75
Luca Valenti
13 days
RT @MichaelAlbertMD: 🚨BREAKING: FDA grants accelerated approval to Wegovy (semaglutide 2.4 mg injection) for treating adults with non‑cirrh….
0
159
0
@lucavalenti75
Luca Valenti
13 days
RT @massimoiava: Additional indication for semaglutide 2.4 mg for treatment of non cirrhotic #MASH in adults with moderate to advanced live….
Tweet card summary image
novonordisk.com
0
4
0
@lucavalenti75
Luca Valenti
15 days
Check out our latest review on MASLD! A metabolic liver disease. Fresh from the press @NEJM @LaStatale @policlinicoMI.
@NEJM
NEJM
15 days
MASLD has become the most common chronic liver disease worldwide. Giovanni Targher, MD, Luca Valenti, MD (@lucavalenti75), and Christopher D. Byrne, MB, ChB, review the features of the disease as well as pharmacotherapies targeting the associated liver and
Tweet media one
9
26
75